1-20 of 60
Scott H. Kaufmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1170: Decitabine (DAC) induces a DNA damage response (DDR) and synergizes with replication checkpoint inhibitors in acute myeloid leukemia (AML)

Clifford M. Csizmar, Antoine N. Saliba, Olivia K. Rossman, Kevin L. Peterson, X. Wei Meng, B. Douglas Smith, Gabriel Ghiaur, Jonathan A. Webster, Mrinal M. Patnaik, Aref Al-Kali, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1170.
https://doi.org/10.1158/1538-7445.AM2025-1170
Published: 21 April 2025
View articletitled, Abstract 1170: Decitabine (DAC) induces a DNA damage response (DDR) and synergizes with replication checkpoint inhibitors in acute myeloid leukemia (AML)
Journal Articles

Abstract 7118: Clinical characteristics and survival outcomes of ovarian cancer among South Asian women in United States

Aditi Karki, Sumeet Kumar Yadav, Muhammad Rafiqul Islam, Raja Pramanik, Ramila Shilpakar Dangol, Zeba Aziz, Sandhya Pruthi, Maryam Shahi, Jamie N. Bakkum-Gamez, Scott H. Kaufmann, Fergus J. Couch, Siddhartha Yadav
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7118.
https://doi.org/10.1158/1538-7445.AM2025-7118
Published: 21 April 2025
View articletitled, Abstract 7118: Clinical characteristics and survival outcomes of ovarian cancer among South Asian women in United States
Journal Articles

Abstract 4538: Brigatinib induces synergy with PARP inhibitors through dual inhibition of FAK and EphA2 in high-grade serous ovarian carcinoma

Julie R. Duffield, Xiaonan Hou, Iman K. McKeon-Makki, Amelia M. Huehls, Benjamin W. Wilson, Anjali Prasad, Xinyan Wu, Scott H. Kaufmann, Larry M. Karnitz, John J. Weroha, Arun Kanakkanthara
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4538.
https://doi.org/10.1158/1538-7445.AM2024-4538
Published: 22 March 2024
View articletitled, Abstract 4538: Brigatinib induces synergy with PARP inhibitors through dual inhibition of FAK and EphA2 in high-grade serous ovarian carcinoma
Journal Articles

Abstract 4447: ZC3H18: A novel regulator of NAD+ metabolism in high-grade serous ovarian cancer

Benjamin Wilson, Natalie Wilson, Xianfeng Chen, Shuwen Zhang, Chen Wang, Larry M. Karnitz, Scott H. Kaufmann, Arun Kanakkanthara
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4447.
https://doi.org/10.1158/1538-7445.AM2024-4447
Published: 22 March 2024
View articletitled, Abstract 4447: ZC3H18: A novel regulator of NAD+ metabolism in high-grade serous ovarian cancer
Journal Articles

Abstract B098: Impact of dexamethasone on chemotherapy response in ovarian cancer

Annapoorna Venkatachalam, Cristina Correia, Cordelia Mcgehee, Sarah Finstuen-Magro, Paula A. Schneider, Rachel Hurley, Kevin L. Peterson, Ethan Heinzen, Melissa C. Larson, Xiaonon Hou, Ann L. Oberg, Saravut Weroha, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): B098.
https://doi.org/10.1158/1538-7445.OVARIAN23-B098
Published: 04 March 2024
View articletitled, Abstract B098: Impact of dexamethasone on chemotherapy response in ovarian cancer
Journal Articles

Abstract B012: Transcriptomic insights reveal role of BCL2 proteins in replication checkpoint inhibitor response

Annapoorna Venkatachalam, Cristina Correia, Kevin L. Peterson, Xiaonan Hou, Annabella R. Strathman, Paula A Schneider, Karen S. Flatten, Laura N. Duffield, Cordelia D. McGehee, Melissa C. Larson, Xue Meng, Nicole D Vincelette, Ann L. Oberg, Hu Li, John Weroha, Scott H Kaufmann
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): B012.
https://doi.org/10.1158/1538-7445.OVARIAN23-B012
Published: 04 March 2024
View articletitled, Abstract B012: Transcriptomic insights reveal role of BCL2 proteins in replication checkpoint inhibitor response
Journal Articles

Abstract 5058: Impact of dexamethasone on chemotherapy response in ovarian cancer

Annapoorna Venkatachalam, Cristina Correia, Cordelia D. Mcgehee, Sarah Finstuen-Magro, Jamison VanBlaricom, Paula A. Schneider, Kevin L. Peterson, Ethan P. Heinzen, Melissa C. Larson, Xiaonon Hou, Ann L. Oberg, Saravut John Weroha, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5058.
https://doi.org/10.1158/1538-7445.AM2023-5058
Published: 04 April 2023
View articletitled, Abstract 5058: Impact of dexamethasone on chemotherapy response in ovarian cancer
Journal Articles

Abstract 4724: Single cell multiomic profiling of high-grade serous carcinoma

Leticia Assad Maia Sandoval, Wazim Mohammed Ismail, Amelia Mazzone, Amik Munankarmy, Jagneet Kaur, Tsering Tashi, Xiaonan Hou, Nagarajan Kannan, Ann Oberg, Scott H. Kaufmann, Saravut John Weroha, Alexandre Gaspar-Maia
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4724.
https://doi.org/10.1158/1538-7445.AM2023-4724
Published: 04 April 2023
View articletitled, Abstract 4724: Single cell multiomic profiling of high-grade serous carcinoma
Journal Articles

Abstract 1832: CHK1 inhibitor prexasertib induces NOXA-dependent apoptosis in ovarian cancer

Annapoorna Venkatachalam, Kevin L. Peterson, Cristina Correia, Karen S. Flatten, Xianon Hou, Paula A. Schneider, Emily Balczewski, Cordelia McGehee, Rachel M. Hurley, Xue W. Meng, Chance Sine, Rameen Shah, Nicole Vincelettte, Husheng Ding, Hu Li, Saravut (John) Weroha, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1832.
https://doi.org/10.1158/1538-7445.AM2022-1832
Published: 15 June 2022
View articletitled, Abstract 1832: CHK1 inhibitor prexasertib induces NOXA-dependent apoptosis in ovarian cancer
Journal Articles

Abstract 1226: A genome wide pharmacological perturbation platform

Cristina Correia, Choong Yong Ung, Cheng Zhang, Scott H. Kaufmann, Hu Li
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1226.
https://doi.org/10.1158/1538-7445.AM2022-1226
Published: 15 June 2022
View articletitled, Abstract 1226: A genome wide pharmacological perturbation platform
Journal Articles

Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer

Upasana Ray, Deok-Beom Jung, Ling Jin, Yinan Xiao, Subramanyam Dasari, Sayantani Sarkar Bhattacharya, Prabhu Thirusangu, Julie K. Staub, Debarshi Roy, Bhaskar Roy, S. John Weroha, Xiaonan Hou, James W. Purcell, Jamie N. Bakkum-Gamez, Scott H. Kaufmann, Nagarajan Kannan, Anirban K. Mitra, Viji Shridhar
Journal: Cancer Research
Cancer Res (2022) 82 (6): 1038–1054.
https://doi.org/10.1158/0008-5472.CAN-21-0622
Published: 15 March 2022
View articletitled, Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer
Open the PDF for Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

Arun Kanakkanthara, Xiaonan Hou, Thomas L. Ekstrom, Valentina Zanfagnin, Amelia M. Huehls, Rebecca L. Kelly, Husheng Ding, Melissa C. Larson, George Vasmatzis, Ann L. Oberg, Scott H. Kaufmann, Aaron S. Mansfield, S. John Weroha, Larry M. Karnitz
Journal: Cancer Research
Cancer Res (2022) 82 (2): 307–319.
https://doi.org/10.1158/0008-5472.CAN-21-0732
Published: 15 January 2022
View articletitled, Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Open the PDF for Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma in another window
Includes: Supplementary data
Journal Articles

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo-Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield-Artin, Marc Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I. Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Australian Ovarian Cancer Study, Anna DeFazio, David D.L. Bowtell, Elizabeth M. Swisher, S. John Weroha, Katia Nones, Nicola Waddell, Scott H. Kaufmann, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott
Journal: Cancer Research
Cancer Res (2021) 81 (18): 4709–4722.
https://doi.org/10.1158/0008-5472.CAN-21-0774
Published: 15 September 2021
View articletitled, Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
Open the PDF for Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma in another window
Includes: Supplementary data
Journal Articles

CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia

Husheng Ding, Nicole D. Vincelette, Cordelia D. McGehee, Mira A. Kohorst, Brian D. Koh, Annapoorna Venkatachalam, X. Wei Meng, Paula A. Schneider, Karen S. Flatten, Kevin L. Peterson, Cristina Correia, Sun-Hee Lee, Mrinal Patnaik, Jonathan A. Webster, Gabriel Ghiaur, B. Douglas Smith, Judith E. Karp, Keith W. Pratz, Hu Li, Larry M. Karnitz, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2021) 81 (10): 2666–2678.
https://doi.org/10.1158/0008-5472.CAN-20-1504
Published: 15 May 2021
View articletitled, CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia
Open the PDF for CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors

Emily J. Koubek, Brian A. Costello, Jun Yin, Renee M. McGovern, Sarah A. Buhrow, Renee A. Schoon, Carrie A. Strand, Yixing Jiang, Mitesh J. Borad, Naoko Takebe, Scott H. Kaufmann, Alex A. Adjei, Joel M. Reid
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT114.
https://doi.org/10.1158/1538-7445.AM2020-CT114
Published: 15 August 2020
View articletitled, Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors
Journal Articles

Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer

Cassandra L. Moyer, Jennifer Ivanovich, Jessica L. Gillespie, Rachel Doberstein, Marc R. Radke, Marcy E. Richardson, Scott H. Kaufmann, Elizabeth M. Swisher, Paul J. Goodfellow
Journal: Cancer Research
Cancer Res (2020) 80 (4): 857–867.
https://doi.org/10.1158/0008-5472.CAN-19-1991
Published: 14 February 2020
View articletitled, Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer
Open the PDF for Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer in another window
Includes: Supplementary data
Journal Articles

BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

Arun Kanakkanthara, Kiran Kurmi, Thomas L. Ekstrom, Xiaonan Hou, Emma R. Purfeerst, Ethan P. Heinzen, Cristina Correia, Catherine J. Huntoon, Daniel O'Brien, Andrea E. Wahner Hendrickson, Sean C. Dowdy, Hu Li, Ann L. Oberg, Taro Hitosugi, Scott H. Kaufmann, S. John Weroha, Larry M. Karnitz
Journal: Cancer Research
Cancer Res (2019) 79 (23): 5920–5929.
https://doi.org/10.1158/0008-5472.CAN-19-1405
Published: 02 December 2019
View articletitled, BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents
Open the PDF for BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents in another window
Includes: Supplementary data
Journal Articles

Abstract 5885: Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance

Rachel M. Hurley, Ksenija Nesic, Cordelia McGehee, Olga Kondrashova, Maria I. Harrell, Paula A. Schneider, Xiaonan Hou, Cristina Correia, Karen S. Flatten, Giada V. Zapparoli, Alexander Dobrovic, Kevin K. Lin, Thomas C. Harding, Andrea E. Wahner Hendrickson, Elizabeth M. Swisher, Matthew Wakefield, S. John Weroha, Clare L. Scott, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5885.
https://doi.org/10.1158/1538-7445.AM2018-5885
Published: 01 July 2018
View articletitled, Abstract 5885: Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance
Journal Articles

Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort

Panagiotis A. Konstantinopoulos, William T. Barry, Michael Birrer, Shannon N. Westin, Sarah Farooq, Karen Cadoo, Christin Whalen, Weixiu Luo, Hui Liu, Carol Aghajanian, David B. Solit, Gordon B. Mills, Barry S. Taylor, Helen Won, Michael F. Berger, Sangeetha Palakurthi, Joyce F. Liu, Lew Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D'Andrea, Eric Winer, Gerburg M. Wulf, Ursula A. Matulonis
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT008.
https://doi.org/10.1158/1538-7445.AM2017-CT008
Published: 01 July 2017
View articletitled, Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Journal Articles

Abstract 3479: CPX-351 (cytarabine:daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition

Nicole D. Vincelette, Larry M. Karnitz, Judith E. Karp, Douglas B. Smith, Allan D. Hess, Lawrence D. Mayer, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3479.
https://doi.org/10.1158/1538-7445.AM2015-3479
Published: 01 August 2015
View articletitled, Abstract 3479: CPX-351 (cytarabine:daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition